Go Pro
NASDAQ:TNON

Tenon Medical Q2 2026 Earnings Report

Tenon Medical logo
$0.20 0.00 (-0.89%)
As of 12:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tenon Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Tenon Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.54 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenon Medical Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Tenon Medical Earnings Headlines

Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
See More Tenon Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenon Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenon Medical and other key companies, straight to your email.

About Tenon Medical

Tenon Medical (NASDAQ:TNON) is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue. Lead indications under investigation include soft tissue repair in general and vascular surgery, hernia reinforcement and leak prevention in gastrointestinal procedures. The company advances its candidates through preclinical studies and early-stage clinical evaluations while working with contract manufacturing organizations to scale production in anticipation of regulatory submissions.

Incorporated in 2012, Tenon Medical is led by a management team with backgrounds in medical device innovation, regulatory affairs and commercial development. Headquartered in the United States, the company maintains collaborations with academic institutions and strategic partners to accelerate its development programs. Tenon Medical’s shares trade on the NASDAQ under the ticker symbol TNON.

View Tenon Medical Profile